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Abstract Mitogen activated protein kinase in extracts of U-937 
macrophage-like cells was stimulated by LDL and oxLDL. A 
maximum value (161% of the basal phosphotransferase activity) 
was obtained after 6 min exposure to oxidized LDL (27 Ixg/ml) 
using APRTPGGRR peptide substrate. The activatory effect 
was more pronounced (LDL 181%, oxLDL 201%) when MAPK 
of stimulated cells was immnnoprecipitated with anti-p42 MArK 
antibodies and phuspho~ransferuse activity was assayed in 
immune complexes. Stimulation produced by oxLDL was 
inhibited by poly I, fucoidan, dextran sulfate and by the 
MAPKK inhibitor PD 098059 but not by PMA-mediated 
depletion of PKC or by pre-treatment with chioroquine or with 
pertussis toxin. These results suggest a direct mitogenic effect of 
LDL which, in the case of oxLDL, is dependent on scavenger 
receptor llgation but not on G-protein mediated or PKC- 
dependent signal transduction. 
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1. Introduction 
Mitogen activated protein kinase plays a key role in cellular 
regulation. The enzyme is a substrate for receptor protein 
tyrosine kinases and serves as a link between membrane 
bound tyrosine kinases and intracellular targets regulated by 
serine/threonine phosphorylation [1,2]. Treatment of cells with 
growth factors as well as with various other extracellular stim- 
uli leads to activation of MAPKs (ERKs). Besides regulation 
of the activity of other serine/threonine kinases, MAP kinases 
are involved in the regulation of gene expression, cell growth, 
differentiation and cytoskeletal function [3-5]. 
Cellular proliferation has been reported to be stimulated by 
LDL in combination with serum [6,7] or with growth factors 
[8,9] and chemically modified LDLs, such as oxLDL and 
acLDL, induce macrophage growth [10]. Consistently, macro- 
phage derived foam cells, generated by uptake of modified 
LDL through the scavenger receptor pathway [11], tend to 
proliferate in atherosclerotic lesions [12,13]. In the investiga- 
tion of causes and consequences of atherosclerotic alterations, 
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the role of oxidatively modified LDL is of particular interest 
[14]. However, although there are numerous investigations 
which deal with mitogenic properties of lipoproteins [9,15], 
whether mitogenic activity is an intrinsic property of LDL 
or oxLDL is still a matter of debate. In this respect, our study 
was performed to examine direct lipoprotein induced effects 
on mitogen activated protein kinase. 
2. Materials and methods 
2.1. Materials 
Human U-937 cells were from DSM (Braunschweig, Germany); 
glutamine, streptomycin, BSA (fatty acid free), sucrose, ethylenedia- 
minetetraacetic acid (EDTA), ethyleneglycol-bis([~-aminomethylether)- 
N,N,N',N'-tetraacetic a id (EGTA), dithiothreitol (DTT), aprotinin, 
leupeptin, benzamidine, phenylmethylsulfonyl fluoride (PMSF), poly- 
inosinic acid, dextran sulfate, fucoidan, phorbol-12-myristate-13-acet- 
ate (PMA), E-Toxate, agarose immobilized phospholipase A2 (10 U/ 
200 lal) and protein A agarose were purchased from Sigma (Deisen- 
hofen, Germany). Polyclonal anti-p42 MAPK antibodies and the MAP 
kinase substrate peptide (APRTPGGRR) were purchased from Bio- 
mol (Hamburg, Germany). Fetal calf serum (FCS), Triton X-100, N- 
[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES) were 
obtained from Boehringer Mannheim (Mannheim, Germany), 
RPMI 1640 medium was purchased from Gibco BRL (Eggenstein, 
Germany), penicillin from Gruenenthal (Stolberg, Germany). Silica 
gel (grade 60, 70230 mesh) for column chromatography was from 
Machery-Nagel (Diiren, Germany), all other reagents were purchased 
from Fluka (Neu-Ulm, Germany), Aldrich (Steinheim, Germany) and 
E. Merck (Darmstadt, Germany). Materials for cell culture were 
products of Nunc (Wiesbaden, Germany) and Greiner (Frickenhau- 
sen, Germany). 7-[32P]ATP (3000 Ci/mM) was from Amersham 
(Braunschweig, Germany). Protein concentration was determined in
a BioRad 450 microplate reader (Munich, Germany) using the BCA 
reagent from Pierce Chemical Co. (Rockford, IL, USA) with albumin 
as standard. 
2.2. Cell culture 
The human cell line U-937 [16] was cultured at 37°C in RPMI 1640 
supplemented with glutamine (2 mM), 10% heat inactivated FCS, 
penicillin (50 U/ml) and streptomycin (50 ~tg/ml) in a humidified at- 
mosphere (5% CO2 in air). Monocytes were differentiated to resident 
macrophage-like cells by addition of 40 nM PMA (72 h) as described 
[17]. Cells were then cultured for another 48 h without PMA, plated 
at the indicated ensity, washed with serum free medium or buffer as 
indicated to remove non-adherent cells, then incubated with the re- 
spective stimuli for various time periods in serum free medium. PKC 
depletion prior experimentation was achieved by PMA treatment (18 
h, 200 nM) of differentiated, macrophage-like cells and was confirmed 
by the absence of PKC 0~ and [3 isozymes as determined by Western 
blot analysis (Western blotting of PKC isoforms was performed ac- 
cording to [18]). In some experiments, cells were cultured with lipo- 
protein-deficient serum (prepared by ultracentrifugation f FCS, 
p)l.21 according to Havel et al. [19]) for 48 h prior to experimenta- 
tion. 
2.3. Low density lipoprotein (LDL) : preparation and oxidation 
LDL was isolated from pooled human plasma containing EDTA (1 
mM) by sequential flotation in an ultracentrifuge at preselected den- 
sities (between 1.019 and 1.063 g/ml) as described [19] and dialyzed 
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extensively against Tris buffer (20 mM, pH 7.8, 150 mM NaCI, 0.2 
mM EDTA). LDL samples were kept sterile under nitrogen in Tris 
buffer at 4°C and used within 2 weeks. Prior to oxidation, LDL was 
stored over polymyxin B agarose for at least 24 h, the polymyxin 
suspension removed by centrifugation and the supernatant passed 
through a polymyxin B agarose column (2 ml) using sterile, non-pyro- 
genic single-use material for intravenous application; the eluate then 
was dialyzed against Tris buffer (without EDTA). All preparations 
were then tested (also subsequent to oxidation) for absence of endo- 
toxin. Endotoxin tests were carried out using E-Toxate. Oxidation of 
LDL was initiated by addition of CuSO4 (20 p-M), followed by in- 
cubation continued for up to 24 h at 37°C under sterile conditions; 
reactions were terminated by addition of EDTA (0.2 mM). 
For determination of binding/uptake according to Tokuda et al. 
[20] [12~I]LDL (7.70 TBq/mM), prepared as described previously 
[21], was diluted with unlabelled LDL to attain a specific activity of 
345 kBq/mg protein. 
Treatment of oxidized LDL with phospholipase A2 was carried out 
by incubation with 2 U immobilized phospholipase/80/.tg lipoprotein 
(1 h, 37°C), the suspension then was removed by centrifugation 
(1500×g, 4 min). 
2.4. Preparation of maleylated BSA 
Albumin was modified with maleic anhydride as reported by Butler 
and Hartley [22]. Briefly, maleic anhydride in dioxane (80 /al, 1 M) 
was added to 20 mg BSA (10 mg/ml) in 0.1 M potassium pyropho- 
sphate buffer (pH 8.5). The mixture was stirred on ice and the pH 
adjusted to 9.0 with NaOH (1 M). After 5 min, 2 ml of 0.5 M sodium 
phosphate buffer (pH 7.4) was added, the sample dialyzed against 
PBS or passed through a Bio-Rad P-6DGel column and checked 
for absence of endotoxin as described above. The modification was 
controlled by agarose gel electrophoresis (30 mA, 50 V, 1.5 h, 1.0% in 
Tris/CH3COOH, pH 8.3, 8 mM supplemented with EDTA (0.2 mM)). 
Protein staining was carried out with Coomassie blue R250 or with 
the Silverstain kit from Bio-Rad. 
2.5. MAP kinase assay 
The cells (3 × 106/dish unless stated otherwise) were treated with the 
lipoproteins and other agents for various times in serum free RPMI 
1640 medium as described above. Following incubation, the cells were 
washed twice and scraped into 1 ml medium, isolated by centrifuga- 
tion at 1500×g for 0.5 min at 4°C, washed with 1 ml ice-cooled PBS, 
and resuspended in 50 p-I homogenization buffer (20 mM HEPES, pH 
7.4, containing 2 mM EDTA, 2 mM EGTA, 2 mM DTT, 300 mM 
sucrose, 10/ag/ml aprotinin, 10/ag/ml leupeptin, 10 p-g/ml PMSF, 0.2 
mM sodium vanadate and 10 p-g/ml benzamidine). The homogenates 
were fast-frozen in liquid nitrogen and stored at -80°C for up to 
2 weeks. After thawing, samples were sonicated at 0°C for 30 s, 
centrifuged at 20000×g and cytosolic MAP kinase activity deter- 
mined in the supernatant by measuring the incorporation of 7- 
[a2p]ATP into a fragment of myelin basic protein, peptide 
(APRTPGGRR) [23]. The reaction was started by addition of 10 p-I 
substrate peptide (250 p_M) and 10 p-1 7-[32p]ATP (0.4 raM, 90000 
kBq/sample) to a mixture of 20 p-I cell lysate (80 p-g protein) and 10 
p-1 reaction buffer (100 mM Tris-HC1 pH 7.0, 0.4 mM EGTA, 0.4 mM 
sodium vanadate, 40 mM Mg(CH3COOH)2). After incubation for 10 
min at 25°C, phosphorylation was terminated by addition of trichlor- 
oacetic acid (10 p-l, 40%) and an aliquot (40 /al) transferred to a 
Whatman phosphocellulose filter (P81, 4 cm2). The filters were air- 
dried, washed four times in 75 mM orthophosphoric a id (5 ml/sam- 
pie), dried again and Cerenkov radiation counted on a LKB-Wallac 
RACKBETA (Turku, Finland). Results were corrected by subtraction 
of the average value of three blank samples containing no cellular 
protein. Inhibition with PD 098059 [24] was achieved by 30 min treat- 
ment of cells with 60 /aM PD 098059 (80 mM stock solution in di- 
methyl sulfoxide/ethanol, 1 : 1, v/v) prior to the addition of oxLDL. 
2.6. Immune complex assay 
Precipitation was carried out with cell lysate in homogenization 
buffer diluted with PBS (1 p-g/lal cell protein) which was treated 
with the antibodies (5 p-g/sample) for 12 h at 4°C. The immune com- 
plex was captured with 100 p-1 protein A agarose (2 h incubation, 4°C) 
and isolated by brief centrifugation at 14000×g. The pellet was 
washed three times with ice-cooled PBS (pH 7.4), resolubilized in 40 
p-1 of reaction buffer (0.2% Triton X-100), centrifuged and phospho- 
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transferase activity of the supernatant was measured as outlined 
above. 
2. 7. Synthesis of the MAPKK inhibitor PD 098059 
3-(2-Amino-3-methoxy-phenyl)-chromen-4-one (PD 098059 [24]) 
was synthesized starting from 3-methoxy-2-nitrobenzoic ac dchloride 
(obtained by reaction of 3-methoxy-2-nitrobenzoic ac d, 1 g, 5 mM 
with PCIs) and 2-hydroxy-acetophenone (495 mg, 3.6 mM) affording 
crude 2-(2-nitro-3-methoxy)-benzoyloxy-acetophenone; the latter in- 
termediate was rearranged to 1-(2-nitro-3-methoxy-phenyl)-3-(2-hy- 
droxy-phenyl)-propane-l,3-dione with potassium hydroxide and sub- 
sequently converted to 3-(2-nitro-3-methoxy-phenyl)-chromen-4-one 
with sulfuric acid/acetic acid at standard conditions [25]. Subsequent 
reduction of the nitro group to the corresponding amine 3-(2-amino- 
3-methoxy-phenyl)-chromen-4-one (PD 098059) was accomplished 
with raney-Ni/hydrazine in ethanol as described [26] and the product 
purified by silica gel chromatography using ethylacetate/chloroform/ 
methanol 10/10/1, v/v as elution agent (total yield (not optimized, 
without purification of intermediates) 211 mg, 22% referring to 2- 
hydroxy-acetophenone). Identity and purity were confirmed by mass 
spectroscopy recorded on a MAT 311 A (Varian, Bremen, Germany) 
(70 eV, electron impact mode): m/z (%)= 267 (60.95) [M]--, 250 
(8.87), 224 (20.4), 147 (100), 57 (48.8) and by elemental nalysis (car- 
ried out on a vario EL, Foss Heraeus, Hanau Germany): Ca6H13NO3 
(267.28) calculated (%): C 71.90, H 4.90, N 5.24; found: C 71.77, H 
4.98, N 5.02. 
3. Results 
When differentiated resident U-937 cells were exposed to 
oxidized LDL (27 ~tg/ml) and the cell lysates were examined 
for MAPK activity as determined by phosphorylation of an 
MBP fragment (peptide APRTPGGRR) ,  we found that the 
modified lipoprotein significantly stimulated phosphotransfer- 
ase activity. As depicted in Fig. 1A, activation was maximal 
after 6 rain of oxLDL treatment. Using a standard exposure 
time to oxLDL of 6 min, we then investigated concentration 
dependence and the effects of potentially inhibitory or stimu- 
latory agents/procedures to get further insight into the stimu- 
latory mechanisms involved. When increasing amounts of 
LDL or oxLDL were applied, a concomitant increase of 
MAPK activity was observed. Maximal stimulation (LDL 
239%, oxLDL 176%) and apparent saturation was found in 
both cases at a concentration about 160 ~g/ml (Fig. 1B), at 
concentrations >27 ~g/ml, the LDL effect exceeded the 
oxLDL mediated one. The curve of the binding/uptake as 
determined with radioiodinated lipoproteins (Fig. 1B, inset) 
exhibited a shape similar to the dose-effect relationship and 
at a concentration >27 p.g/ml, significantly more [125I]LDL 
than [125I]oxLDL was bound. 
Treatment of LDL with phospholipase A2 subsequent to 
oxidation further increased the stimulatory effect of oxLDL 
(27 p.g/ml) (Fig. 2). A degree of activation similar to that 
obtained with oxLDL was achieved by administration of Ly- 
soPAF (200 nM) whereas plain PMA (200 nM) caused only 
little increase in phosphotransferase activity (not shown). 
When cells were cultured in lipoprotein deficient serum, stim- 
ulation provided by LDL was somewhat enhanced 089%, 
Fig. 2, in comparison to 164%, Fig. 1B) whereas the effect 
of oxLDL was unaltered. Pre-exposure to the inhibitor of 
lysosomal degradation chloroquine [27] (20 ktM) could not 
prevent activation of MAPK by oxLDL. However, this result 
was achieved by competition with the scavenger receptor li- 
gands poly I (40 ~g/ml), fucoidan (10 ktg/ml) (Fig. 2) and 
dextran sulfate (10 /~g/ml, not shown). Furthermore, poly I 
somewhat reduced kinase activation by LDL. Control experi- 
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Fig. 1. (A) Differentiated U-937 cells (3×106) were treated with 
oxLDL (27 ~tg/ml) for the time indicated and the capacity of cell ex- 
tracts to phosphorylate APRTPGGRR substrate peptide was meas- 
ured as described in section 2; the data are representative of two se- 
parate experiments with triplicate determinations. (B) Increase of 
phosphotransferase activity with the lipoprotein concentration; 
macrophage-like U-937 cells were incubated (6 min) with increasing 
amounts of LDL or oxLDL and the capacity of cell extracts to cat- 
alyze APRTPGGRR peptide phosphorylation was assayed. Inset: 
the concentration-dependent bi ding/uptake of [125I]oxLDL and 
[125I]LDL was determined after 6 min incubation (displayed as ng/ 
mg cell protein). Results are presented as the mean + S.D. for tripli- 
cate determinations of a representative experiment. 
ments confirmed that neither poly I, fucoidan nor dextran 
sulfate affected phosphorylation of the substrate peptide in 
the absence of lipoproteins (not shown). Consistent with an 
activation by mitogens, LPS (1 p.g/ml) greatly increased the 
transfer of labeled phosphate to the peptide. 
To confirm the activation of MAPK via MAPK kinase and 
to determine the relative contribution of this pathway to the 
observed oxLDL induced stimulation of peptide phosphoryla- 
tion, the recently discovered inhibitor of MEK, PD 098059 
[24], was synthesized and its effect on oxLDL induced MAPK 
activation examined. The agent (60 p.M) completely blocked 
the effect of oxLDL, addition of the compound alone however 
did not alter the constitutive l vel of MAPK activity. 
In order to eliminate the background of peptide phosphor- 
ylation probably caused by the contributions of other kinases 
and to further establish p42 MAP~ specificity of activation, ex- 
periments were carried out using immunoprecipitated enzyme. 
In this set of experiments he relative increase in phospho- 
transferase activity stimulated by oxLDL was greater than 
the enhancement induced in cellular extracts (averaging at 
approx. 200%) (Fig. 3). Pre-exposure of the cells to pertussis 
toxin (0.1 ~tg/ml, 24 h) did not affect this result and moreover, 
oxLDL induced stimulation was not abolished by PMA 
mediated down-regulation of PKC. MalBSA and native 
LDL (both 27 ~tg/ml) produced a stimulation (LDL 181%, 
malBSA 192%) similar to that caused by oxLDL. As observed 
with the total cell extracts, maximal activation (231%) was 
achieved with LPS (1 ~tg/ml). 
4.  D iscuss ion  
We found that LDL and oxLDL both can activate MAPK. 
The short exposure time required for activation as well as the 
absent effect of chloroquine, an inhibitor of lysosomal degra- 
dation [27], supports the suggestion of direct signal transduc- 
tion subsequent to receptor occupation. 
The effect of the inhibitor of MAPKK activation PD 
098059 [28] on oxLDL induced MAP kinase stimulation and 
the reduction observed after administration f the SR ligands 
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Fig. 2. Phosphotransferase ctivity (APRTPGGRR substrate pep- 
tide) of resident differentiated U-937 cell extracts was assayed after 
treatment with oxLDL (6 min, 27 I.tg (protein)/ml), PLA2 treated 
oxLDL (2 U, 1 h) and/or with other stimuli/inhibitors; concentra- 
tions employed: LPS 1 p.g/ml, ysoPAF 200 nM, poly I 40 ~tg/ml, 
fucoidan 10 ~g/ml, chloroquine 20 ~tM, PD 098059 60 jaM. Pretreat- 
ment of cells with selected agents (PD 098059, chloroquine, poly I, 
fucoidan, prior to the addition of oxLDL) was performed by incu- 
bation for 30 min. The open bars designate data obtained with cells 
cultured in lipoprotein deficient medium for 48 h. For LDL and 
oxLDL induced changes (without further additions) see Fig. lb. 
The data are expressed asthe means + S.D. of two experiments with 
triplicate determinations. 
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Fig. 3. Cells (1 × 107) were incubated with LDL, oxLDL, malBSA 
(all 27 btg/ml, 6 min), broken and MAPK precipitated with limiting 
amounts of polyclonal anti-p42 MAPK antibodies. The isolated preci- 
pitates were washed, solubilized and MAPK activity was measured 
as described in section 2. As indicated, cells were pretreated with 
PMA (200 nM, 18 h) or pertussis toxin (0.1 ~g, 24 h) for depletion 
of PKC or to block G-protein dependent processes; average values 
of three experiments + S.D. are given. 
transduction of signals starting with the occupation of scaven- 
ger receptors followed by subsequent steps involving MEK 
dependent activation of MAPK. Almost complete reduction 
of the phosphorylating capacity (close to control levels) by 
addition of PD 098059 prior to oxLDL further indicates 
that most of the (oxLDL produced) increase in phosphotrans- 
ferase activity in cell extracts is due to stimulation of MAPK 
activity. Although these observations suggest that binding/up- 
take via scavenger receptors i mandatory, plain occupation of 
SR (as provided by polyanionic ligands like poly I) apparently 
is not sufficient. Consistently, growth induced by oxLDL has 
been described to be inhibitable by polyinosinic acid [10]. The 
partial blocking of the LDL induced effect by this agent might 
be explained by (potentially formed) poly I -LDL complexes 
and corresponding alterations in the receptor mediated uptake 
of these particles. 
Results obtained with oxidized LDL and cell extracts could 
be confirmed by experiments carried out on immunoprecipi- 
tated kinase and we observed that malBSA also activates 
MAPK. In this context it is of note that maleylated albumin 
can replace the mitogen LPS in activating primed macro- 
phages [29,30]. However, the assignment of such effects to 
specific receptors in this case requires further elucidation since 
Haberland and colleagues [31] have shown that maleylated 
albumin interacts with an additional binding site, distinct 
from the scavenger eceptor in human monocytes/macro- 
phages. 
Resink and colleagues [15] have demonstrated that oxidized 
LDL as well as chemically modified LDL (acLDL, malondial- 
dehyde modified LDL) were similar to LDL in stimulating 
DNA and protein synthesis in smooth muscle cells. These 
authors also suggested that the activation of mitogenic signals 
by lipoproteins does not depend on lipid peroxidation but 
may depend on direct activation of replication coupled signal 
transduction systems. Others [32], however, have stated that 
the growth stimulating effect of the chemically modified lipo- 
protein acLDL on murine macrophages was negligibly weak 
compared with that of oxLDL. Under our conditions, the 
addition of LDL provoked a similar (to equal amounts of 
oxLDL) stimulation of MAPK activity at concentrations 
-<27 ~tg/ml and an even greater effect at >27 Ixg/ml, suggesting 
that both lipoproteins elicit similar (MAPK dependent) 
growth related effects. Contradictions are likely to be related 
to different numbers (and different ypes, apoB/E receptors or 
SR) of receptors available in distinct cell lines. We have 
shown that the shape of the dose-response curves for LDL 
and oxLDL induced MAPK activation was similar to the 
curve obtained for the binding/degradation f the radioiodi- 
nated lipoproteins. Although parameters obtained from de- 
gradation assays generally represent metabolism of the ligand 
at steady state rather than binding at equilibrium [33], the 
apparent dissociation constants determined at 37°C were 
found to be very similar to those determined for binding, 
uptake and degradation [34-36]. Hence, our data suggest a 
dose-response r lationship of scavenger or apoB/E receptor 
binding/degradation a d MAPK stimulation. Culturing of 
the cells in lipoprotein deficient serum produced only a small 
additional increase of MAPK activity in LDL stimulated cells 
indicating poor up-regulation of LDL receptors by this pre- 
treatment. However, this result agrees with the previous ob- 
servation of Hayashi and colleagues [17] who conversely 
found only sluggish down-regulation of LDL receptors in dif- 
ferentiated U-937 cells upon cholesterol accumulation. 
Among the components of LDL/oxLDL, there are several 
agents with potential mitogenic activity; e.g. oxidation of 
LDL is accompanied by the generation of lysophospholipids 
[37]. The presence of lysophospholipids in oxLDL is most 
probably due to the activity of the LDL associated PAF acet- 
ylhydrolase capable of hydrolyzing PAF-like compounds gen- 
erated during oxidative fragmentation of LDL phospholipids 
[38,39]. In support of this interpretation, it has been demon- 
strated [32] that lysophosphatidylcholine s essential to the 
mitogenic effect of oxLDL on murine macrophages. These 
authors also described a treatment of acLDL with phospho- 
lipase A2 which caused an increase in lysophosphatidylcholine 
concentration aswell as an enhanced mitogenic activity of this 
lipoprotein. We found that incubation of oxLDL with phos- 
pholipase A2 further stimulated phosphorylation of the sub- 
strate peptide which provides evidence of a stimulatory effect 
of lysophosphocholines. On the other hand, a recent report 
indicates that oxLDL contains phospholipids with PAF-like 
activity which are generated along with the oxidation of LDL 
and may account for mitogenic effects and stimulated growth 
of smooth muscle cells [40]. The fact that the mitogenic effect 
of oxLDL could be abolished by pretreatment with PAF acet- 
ylhydrolase supports this interpretation. Accordingly, LDL 
associated PAF-acetylhydrolase, just like the hydrolysis pro- 
vided by exogenous phospholipases, may increase the mito- 
genic potential of oxidizing LDL by generation of lysopho- 
sphocholines. However, it may also cause the opposite ffect, 
a reduction due to the hydrolysis of PAF-like compounds. 
Our data are compatible with the first mentioned possibility 
that LDL associated acetylhydrolase may increase the mito- 
genic potential of oxLDL. This assumption is also supported 
by the finding that PAF receptor mediated events (in murine 
macrophage-like c lls) can be blocked by pertussis toxin [41], 
an observation which (unlike e.g. activation of MAPK by 
sphingophosphorylcholine [42]) we did not note for oxLDL 
induced activation of MAPK. Further analysis, however, will 
require (quantitative) consideration of the number/affinity of 
the respective receptors involved as well as a quantitation of 
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lysophosphocholines and PAF-like compounds of the respec- 
tive particle. Furthermore, conclusions based on experimental 
data must account for the possibility that the presence of 
PAF-acetylhydrolase activity (during the oxidation of LDL) 
is likely to alter the modification as well as the binding/uptake 
of the resulting modified particle by scavenger eceptors 
[43,44]. 
Lysophosphatidylcholine may modulate the effects induced 
by PKC activation [45] and we could demonstrate recently 
that oxLDL stimulates PKC activity in murine macrophage- 
like cells [46]. The results of this study, however, suggest hat 
p42 ~IAPr~ activation by oxidized LDL is independent of PKC 
activity (or activation) as shown by down-regulation of PKC 
following a prolonged treatment of the cells with phorbol 
ester. 
In conclusion, our data support the notion that LDL and 
oxLDL both exert intrinsic primary mitogenic properties 
which in the case of the latter particle requires interactions 
with scavenger receptors. 
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